水凝胶间隔物联合立体定向体部放疗治疗前列腺癌的II期研究:急性毒性与倾向性评分匹配比较
主要终点为3个月内医师评估的急性胃肠道毒性。结果显示间隔物显著降低直肠剂量,未降低医师评估的急性毒性,但改善了患者报告的急性肠道毒性。
要点
- 水凝胶间隔物显著降低直肠受照剂量。
- 医师评估的急性GI和GU毒性在有无间隔物组间无显著差异。
- 间隔物组1个月时EPIC肠道评分显著优于对照组(82.2 vs 68.5)。
核心结论
- SBRT联合水凝胶间隔物具有降低直肠剂量的剂量学获益。
- 使用水凝胶间隔物未降低医师评估的急性毒性,但改善了患者报告的急性肠道毒性。
研究设计与样本
- 所有患者接受水凝胶间隔物置入,随后行36.25 Gy/5次容积调强弧形治疗SBRT。
- 主要终点为3个月内医师评估的急性胃肠道毒性,并采用倾向性评分匹配分析比较有无间隔物患者。
主要发现
- 水凝胶间隔物显著降低直肠剂量。
- 2级急性胃肠道毒性和泌尿生殖毒性分别见于7例(18%)和17例(44%)患者。
- EPIC肠道和泌尿总结评分从基线至第1个月下降(P < 0.01,< 0.01),第3个月仍显著低于基线(P < 0.01,P = 0.04)。
- 倾向性评分匹配分析中,两组急性胃肠道和泌尿生殖毒性无显著差异。
- 1个月时EPIC肠道总结评分在间隔物组显著更优(间隔物组82.2,对照组68.5)。
关键数值与推荐
- SBRT剂量方案为36.25 Gy分5次。
- 主要终点为3个月内医师评估的急性胃肠道毒性。
- 2级急性胃肠道毒性发生率为18%(7例),2级急性泌尿生殖毒性发生率为44%(17例)。
- 1个月EPIC肠道总结评分:间隔物组82.2,对照组68.5。
临床怎么用
- 水凝胶间隔物可用于前列腺癌SBRT以降低直肠剂量。
- 应关注患者报告的肠道毒性改善,而不仅依赖医师评估的急性毒性。
局限性
- 单中心、单臂设计,对照组为历史电子记录数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of a hydrogel spacer in stereotactic body radiotherapy (SBRT) has not been clarified. We evaluated the safety and efficacy of SBRT in combination with a hydrogel spacer for prostate cancer. METHODS: This is a prospective single-center, single-arm phase II study. Prostate cancer patients without lymph node or distant metastasis were eligible. All patients received a hydrogel spacer insertion, followed by SBRT of 36.25 Gy in 5 fractions with volumetric modulated arc therapy. The primary endpoint was physician-assessed acute gastrointestinal (GI) toxicity within 3 months. The secondary endpoints were physician-assessed acute genitourinary (GU) toxicity, patient-reported outcomes evaluated by the EPIC and FACT-P questionnaires, and dosimetric comparison. We used propensity score-matched analyses to compare patients with the hydrogel spacer with those without the spacer. The historical data of the control without a hydrogel spacer was obtained from our hospital's electronic records. RESULTS: Forty patients were enrolled between February 2017 and July 2018. A hydrogel spacer significantly reduced the dose to the rectum. Grade 2 acute GI and GU toxicity occurred in seven (18%) and 17 (44%) patients. The EPIC bowel and urinary summary score declined from the baseline to the first month (P < 0.01, < 0.01), yet it was still significantly lower in the third month (P < 0.01, P = 0.04). For propensity score-matched analyses, no significant differences in acute GI and GU toxicity were observed between the two groups. The EPIC bowel summary score was significantly better in the spacer group at 1 month (82.2 in the spacer group and 68.5 in the control group). CONCLUSIONS: SBRT with a hydrogel spacer had the dosimetric benefits of reducing the rectal doses. The use of the hydrogel spacer did not reduce physician-assessed acute toxicity, but it improved patient-reported acute bowel toxicity. TRIAL REGISTRATION: Trial registration: UMIN-CTR, UMIN000026213. Registered 19 February 2017, https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029385 .
引用
- Ogita M, Yamashita H, Nozawa Y, et al. Phase II study of stereotactic body radiotherapy with hydrogel spacer for prostate cancer: acute toxicity and propensity score-matched comparison. Radiat Oncol. 2021. PMID: 34118956. doi:10.1186/s13014-021-01834-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。